
IIT Kanpur is all set to get a new Centre for Engineering in Medicine soon. According to the official update, IIT Kanpur – one of India’s premier technology institutes, will get a new Centre for Engineering and Medicine soon. The centre is being developed by the institute as part of the MoU signed between IIT Kanpur and United States-based Mehta Family Foundation. Once established the centre will formally be named as ‘The Mehta Family Centre for Engineering in Medicine’.
MoU signed at Institute’s Diamond Jubilee Celebrations
The MoU between IIT Kanpur and the Mehta Family Foundation was signed on the eve of the diamond jubilee celebrations of the institute. The Memorandum of Understanding was formally signed by IIT-K director Abhay Karandikar and Rahul Mehta of the Mehta Family Foundation. Once established, the foundation will appoint Professor Shankar Subramaniam of the University of California, San Diego as the first international advisor to the ‘The Mehta Family Centre for Engineering in Medicine’.
Key Focus Areas
As per the details shared by the institute, the Centre for Engineering in Medicine will have three key focus areas on which it will be conducting active research. These include
- Regenerative Medicine
- Molecular Medicine
- Digital Medicine
Redefine Medical & Healthcare Practices
The centre will actively work towards developing the new field and techniques which will shape the way healthcare is practiced in 21st Century. The new Centre for Engineering in Medicine will look to identify and develop innovative ways to solve challenging medical problems. The centre will amalgamate medicine and engineering domains to come up with new-age solutions for contemporary medical problems faced by people.
The Centre will leverage the strengths of IIT Kanpur in core engineering domains and mate them with department of biological sciences and bioengineering BSBE (biomedical research). This will lead to development of new areas of research that enable more impactful research (fundamental and applied).

Comments
All Comments (0)
Join the conversation